All In Biotech

Drug Trial Radar · NCT07872033

Aleniglipron Hepatic Impairment Study

A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.

Conditions

  • Hepatic Impairment

Interventions

  • AleniglipronDrug

    administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameters including but not limited to AUC0-tTime frame: Baseline to Day 5 (Part 1)
  2. PK parameters including but not limited to AUC0-infTime frame: Baseline to Day 5 (Part 1)
  3. PK parameters including but not limited to CmaxTime frame: Baseline to Day 5 (Part 1)
  4. PK parameters including but not limited to AUC0-tTime frame: Baseline to Day 5 (Part 2)
  5. PK parameters including but not limited to AUC0-infTime frame: Baseline to Day 5 (Part 2)
  6. PK parameters including but not limited to CmaxTime frame: Baseline to Day 5 (Part 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Orlando, Florida · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.